Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $184.6652W HIGH $281.07
Volume
6.40 M
Value Traded
2.34 B
Short % Float
0.7%
Days to Cover
2.0
+1.28%Week
+1.3%1 Month
+5.95%3 Month
+17.92%6 Month
+36.78%5 Year
+37,394.82%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
653.18 B
EPS (TTM)
6.68
P/E Ratio
40.58
Ent. Value
680.60 B
Total Shares
2.41 B
Float Shares
2.40 B
Insiders
0.12%
Institutions
77.34%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
JNJ Catalyst Timeline
Dated clinical, regulatory and corporate events for Johnson & Johnson
Catalyst Timeline
Dated clinical, regulatory & corporate events for Johnson & Johnson
2112Total events
34Upcoming
1057Tier-1 (high impact)
2010 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationAmivantamabApprovedPresentation
Cohort 5 OrigAMI-4 first-line HNSCC data presented as rapid oral presentation at ESMO Congress 2026 (Abstract #1539RO)
recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)source ↗
▲Oral PresentationPresentation
Cohort 5 first-line HNSCC data presented as rapid oral presentation at ESMO Congress 2026 (Abstract #1539RO)
recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)source ↗
▲Topline ReadoutClinical Data
Cohort 5 of OrigAMI-4 shows 77% confirmed ORR in first-line HNSCC (non-HPV OPSCC)
recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)source ↗
▲Dose Finding UpdateJNJ-6143Trial
50-mg once-daily dose of JNJ-6143 selected as preliminary optimal dose for further development
advanced prostate cancer (mAPMR/mCRPC)source ↗
▲Topline ReadoutJNJ-6143Clinical Data
Phase 1 results for JNJ-6143 show 75% tumor response rate in advanced prostate cancer
advanced prostate cancer (mAPMR/mCRPC)source ↗
▲Topline ReadoutApalutamideApprovedClinical Data
PROTEUS substudy results: perioperative apalutamide plus ADT vs surgery alone
high-risk localised or locally advanced prostate cancersource ↗
▲Primary Endpoint MetApalutamideApprovedClinical Data
PROTEUS substudy met primary EFS endpoint with 62% reduction in risk of recurrence or death vs surgery alone
high-risk localized or locally advanced prostate cancersource ↗
▲Secondary Endpoint DataApalutamideApprovedClinical Data
PROTEUS substudy showed 51% lower risk of metastasis or death (MFS) with perioperative apalutamide plus ADT
high-risk localized or locally advanced prostate cancersource ↗
▲Late-BreakerApalutamideApprovedPresentation
PROTEUS substudy results presented as late-breaking abstract at ESMO Congress 2026 (#LBA53)
high-risk localized or locally advanced prostate cancersource ↗
▲Oral PresentationJNJ-6143Presentation
JNJ-6143 Phase 1 data presented in Proffered Paper session at ESMO Congress 2026
advanced prostate cancer (mAPMR/mCRPC)source ↗
▲EU ApprovalTECVAYLIApprovedEx-US Regulatory
European Commission approves TECVAYLI (teclistamab) monotherapy indication extension for RRMM in second line
relapsed/refractory multiple myeloma (RRMM) who have received at least one prior therapysource ↗
▲Late-BreakerPresentation
Late-breaking Omny-IRE 12-month outcomes for investigational OMNYPULSE Platform presented at APHRS 2026
paroxysmal atrial fibrillationsource ↗
▲PublicationPresentation
Omny-IRE 12-month results published in Heart Rhythm
paroxysmal atrial fibrillationsource ↗
▲Late-BreakerPresentation
Late-breaking VARIPURE real-world data for VARIPULSE Pro Platform presented at APHRS 2026
atrial fibrillationsource ↗
▲Poster PresentationPresentation
Poster presentation of 12-month Premier Database analysis comparing CARTO 3 System and EnSite 4 mapping
paroxysmal atrial fibrillationsource ↗
▲Product LaunchPost-Market
U.S. launch of Shockwave C2 Aero Fly Coronary IVL Catheter
calcified coronary artery diseasesource ↗
▲Late-BreakerTREMFYAApprovedPresentation
Late-breaking FUZION 48-week data presented at UEG Week 2026
Crohn's disease with perianal fistulasource ↗
▲Long Term DataTREMFYAApprovedClinical Data
TREMFYA 48-week FUZION results show durable fistula remission
Crohn's disease with perianal fistulasource ↗
▲Long Term DataGuselkumabApprovedClinical Data
TREMFYA 3-year GALAXI data show durable clinical and endoscopic remission in Crohn's disease
moderately to severely active Crohn's diseasesource ↗
▲Late-BreakerGuselkumabApprovedPresentation
Late-breaking FUZION 48-week results presented at UEG Week 2026
Crohn's disease with perianal fistulasource ↗
▲Full ResultsTREMFYAApprovedClinical Data
TREMFYA 48-week FUZION results show durable fistula remission
Crohn's disease with perianal fistulasource ↗
▲CHMP Positive OpinionTALVEYApprovedEx-US Regulatory
CHMP positive opinion recommending approval of TALVEY (talquetamab) plus daratumumab with or without pomalidomide for RRMM
relapsed or refractory multiple myelomasource ↗
▲Primary Endpoint MetTalquetamabApprovedClinical Data
MonumenTAL-3 met primary endpoint with significant PFS improvement for talquetamab plus daratumumab regimens vs DPd
relapsed or refractory multiple myelomasource ↗
▲Secondary Endpoint DataTalquetamabApprovedClinical Data
MonumenTAL-3 secondary endpoint data: ORR, ≥CR, MRD-negative ≥CR and OS improvements for Tal-DP and Tal-D vs DPd
relapsed or refractory multiple myelomasource ↗
●Safety Data UpdateTalquetamabApprovedClinical Data
MonumenTAL-3 safety data update showing consistent safety profiles for talquetamab plus daratumumab arms
relapsed or refractory multiple myelomasource ↗
▲Quarterly UpdateCorporate
Johnson & Johnson reports Q3 2026 results with sales growth of 5.9% to $25.4 billion
▲Subgroup AnalysisTREMFYAApprovedClinical Data
Prespecified subgroup analyses from FUZION show consistent combined fistula remission across key Crohn's disease subgroups
Crohn's disease with perianal fistulasource ↗
▲Long Term DataTREMFYAApprovedClinical Data
Three-year (Week 144) LTE data from GALAXI 2 and 3 show sustained clinical and endoscopic remission
moderately to severely active Crohn's diseasesource ↗
▲Oral PresentationTREMFYAApprovedPresentation
Week 144 GALAXI 2 and 3 LTE results presented at ACG 2026
moderately to severely active Crohn's diseasesource ↗
▲Long Term DataICOTYDEApprovedClinical Data
Two-year ICONIC-LEAD data show sustained skin clearance at Week 112
moderate-to-severe plaque psoriasissource ↗
▲Oral PresentationICOTYDEApprovedPresentation
ICONIC-LEAD 2-year data presented at Fall Clinical Dermatology 2026
moderate-to-severe plaque psoriasissource ↗
▲CHMP Positive OpinionTECVAYLIApprovedEx-US Regulatory
CHMP empfiehlt Zulassung einer Indikationserweiterung für TECVAYLI (teclistamab) bei RRMM nach mindestens einer vorherigen Therapie
rezidiviertes oder refraktäres multiples Myelom (RRMM)source ↗
▲Topline ReadoutCAPLYTAApprovedClinical Data
Positive topline results from pivotal Phase 3 Study 451 of CAPLYTA in bipolar I mania
manic episodes with or without mixed features in adults with bipolar I disordersource ↗
▲Primary Endpoint MetCAPLYTAApprovedClinical Data
Study 451 met primary endpoint with statistically significant 4.8-point greater YMRS reduction vs placebo at Week 3
manic episodes with or without mixed features in adults with bipolar I disordersource ↗
▲Secondary Endpoint DataCAPLYTAApprovedClinical Data
Significant improvement in CGI-S illness severity vs placebo at Week 3 (LSMD -0.5; P<.0001)
manic episodes with or without mixed features in adults with bipolar I disordersource ↗
●Safety Data UpdateCAPLYTAApprovedClinical Data
CAPLYTA well-tolerated in Study 451 with safety profile consistent with established profile
manic episodes with or without mixed features in adults with bipolar I disordersource ↗
▲CHMP Positive OpinionTECVAYLIApprovedEx-US Regulatory
CHMP recommends approval of TECVAYLI indication extension for RRMM after ≥1 prior therapy
relapsed/refractory multiple myeloma after at least one prior therapysource ↗
●Late-BreakerCAPLYTAApprovedPresentation
Study 451 findings presented in late-breaking presentation at 2026 Psych Congress Annual Meeting
manic episodes with or without mixed features in adults with bipolar I disordersource ↗
▲Topline ReadoutAmivantamabApprovedClinical Data
Final overall survival analysis of PAPILLON: median OS 34.3 months with amivantamab plus chemotherapy
EGFR exon 20 insertion mutation-positive non-small cell lung cancersource ↗
▲Topline ReadoutRYBREVANT®ApprovedClinical Data
Final overall survival analysis of PAPILLON presented at IASLC 2026 WCLC Presidential Symposium
EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancersource ↗
▲Oral PresentationRYBREVANT®ApprovedPresentation
PAPILLON final OS results presented at IASLC 2026 WCLC Presidential Symposium (Late-breaking Abstract #PL.03.03)
EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancersource ↗
▲Late-BreakerAmivantamabApprovedPresentation
PAPILLON final OS results presented as late-breaking abstract at IASLC 2026 WCLC Presidential Symposium
EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancersource ↗
▲Oral PresentationAmivantamabApprovedPresentation
PAPILLON final OS results presented at IASLC 2026 WCLC Presidential Symposium
EGFR exon 20 insertion mutation-positive non-small cell lung cancersource ↗
●Poster PresentationRYBREVANT®ApprovedPresentation
COPERNICUS prophylactic strategies data presented at WCLC 2026 (Abstract #MO12.09)
EGFR-mutated non-small cell lung cancersource ↗
●Poster PresentationPresentation
PALOMA-2 subcutaneous administration data presented at WCLC 2026 (Abstract #PT2.03.06)
EGFR-mutated non-small cell lung cancersource ↗
▲Topline ReadoutAmivantamabApprovedClinical Data
Final overall survival analysis of PAPILLON presented at WCLC 2026
EGFR exon 20 insertion mutation-positive non-small cell lung cancersource ↗
▲Other Regulator MilestoneEx-US Regulatory
Johnson & Johnson receives CE marking for reusable ACUVUE OASYS MAX 2-Week contact lenses
▲FDA ApprovalFDA Decision
CE marking received for ACUVUE OASYS MAX 2-Week reusable contact lenses
▲EU ApprovalEx-US Regulatory
CE mark obtained for ACUVUE OASYS MAX 2-Week reusable contact lenses
Past FDA Catalysts and PDUFA Decisions
How JNJ actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-28 | Stelara (ustekinumab) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
92
Drugs Scored
rNPV / MCap
Top Drug
Top 1%
Large Pharma(rank 8 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| DARZALEX | |||
| TREMFYA | |||
| INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | |||
| ERLEADA | |||
| STELARA | |||
| Xarelto | |||
| CARVYKTI | |||
| IMBRUVICA | |||
| Simponi/Simponi Aria | |||
| OPSUMIT/OPSYNVI | |||
| SPRAVATO | |||
| UPTRAVI |
Top 12 of 22 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Icotrokinra Small moleculeNCT06878404 | Arthritis, Psoriatic | Phase 3 | ACTIVE NOT_RECRUITING | 1,302 | Feb 4, 2028 | ||||||
| JNJ-77242113 Small moleculeNCT06295692 | Generalized Pustular Psoriasis | Phase 3 | ACTIVE NOT_RECRUITING | 19 | Oct 14, 2027 | ||||||
| Icotrokinra Small moleculeNCT07196748 | Colitis, Ulcerative | Phase 3 | RECRUITING | 882 | Jan 13, 2032 | ||||||
| Icotrokinra Small moleculeNCT07196722 | Crohn Disease | Phase 2 | RECRUITING | 1,092 | Oct 16, 2032 | ||||||
| Milvexian Small moleculeNCT05757869 | Atrial Fibrillation | Phase 3 | ACTIVE NOT_RECRUITING | 20,284 | Dec 8, 2026 | ||||||
| Milvexian Small moleculeNCT05702034 | Ischemic Stroke; Ischemic Attack, Transient | Phase 3 | ACTIVE NOT_RECRUITING | 12,523 | Oct 15, 2026 | ||||||
| Ramantamig Small moleculeNCT07589634 | Multiple Myeloma | Phase 3 | RECRUITING | 1,230 | Nov 8, 2030 | ||||||
| JNJ-79635322 Small moleculeNCT07266441 | Multiple Myeloma | Phase 3 | ACTIVE NOT_RECRUITING | 1,544 | Dec 12, 2028 | ||||||
| JNJ-79635322 Small moleculeNCT05652335 | Relapsed or Refractory Multiple Myeloma | Phase 1 | RECRUITING | 180 | Nov 15, 2030 | ||||||
| JNJ-78934804 Small moleculeNCT07577856 | Colitis, Ulcerative | Phase 3 | RECRUITING | 644 | Oct 16, 2030 | ||||||
| JNJ-78934804 Small moleculeNCT07577843 | Crohn Disease | Phase 3 | RECRUITING | 460 | Jul 12, 2030 | ||||||
| Amivantamab Monoclonal antibodyNCT06662786 | Colorectal Neoplasms | Phase 3 | RECRUITING | 1,700 | Jan 20, 2032 | ||||||
| Pasritamig Monoclonal antibodyNCT07164443 | Metastatic Castration-resistant Prostatic Neoplasms | Phase 3 | RECRUITING | 1,203 | Aug 18, 2028 | ||||||
| Amivantamab Monoclonal antibodyNCT06385080 | Squamous Cell Carcinoma of Head and Neck | Phase 3 | RECRUITING | 787 | Jul 28, 2033 | ||||||
| Amivantamab Monoclonal antibodyMarketedNCT05488314 | Lung Non-Small Cell Carcinoma | Phase 3 | ACTIVE NOT_RECRUITING | 3,040 | Apr 28, 2027 | ||||||
| Pasritamig Small moleculeNCT07225946 | Prostatic Neoplasms, Castration-Resistant | Phase 3 | RECRUITING | 800 | Jun 7, 2030 | ||||||
| Amivantamab Monoclonal antibodyMarketedNCT02609776 | Non-Small-Cell Lung Cancer | Phase 1 | ACTIVE NOT_RECRUITING | 751 | Dec 31, 2027 | ||||||
| Amivantamab Monoclonal antibodyNCT05379595 | Advanced or Metastatic Colorectal Cancer | Phase 1 | RECRUITING | 225 | May 11, 2031 | ||||||
| Amivantamab Monoclonal antibodyMarketedNCT05845671 | Lung Cancer | Phase 1 | ACTIVE NOT_RECRUITING | 12 | Jan 1, 2028 | ||||||
| Amivantamab Monoclonal antibodyMarketedNCT04606381 | Neoplasms | Phase 1 | ACTIVE NOT_RECRUITING | 158 | Apr 1, 2027 | ||||||
| Pasritamig Small moleculeNCT05818683 | Metastatic Castration-resistant Prostate Neoplasms | Phase 1 | RECRUITING | 300 | May 23, 2028 | ||||||
| JNJ-78278343 Small moleculeNCT04898634 | Prostatic Neoplasms | Phase 1 | ACTIVE NOT_RECRUITING | 711 | Mar 31, 2027 | ||||||
| Pasritamig Small moleculeNCT07319871 | Prostatic Neoplasms | Phase 1 | RECRUITING | 40 | Apr 30, 2027 | ||||||
| Botaretigene sparoparvovec Gene therapyNCT06646289 | X-Linked Retinitis Pigmentosa | Phase 3 | ACTIVE NOT_RECRUITING | 226 | Oct 24, 2030 | ||||||
| Botaretigene sparoparvovec Gene therapyNCT05926583 | Retinitis Pigmentosa | Phase 3 | ACTIVE NOT_RECRUITING | 4 | Nov 12, 2030 |
Clinical Trial Results
Readouts, endpoints and source filings for every JNJ program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| JNJ-6143 | advanced prostate cancer | Phase 1 | 2026-10-25 | tumor response rate: 75%; psa reduction 50 percent: 77%; psa reduction 90 percent: 48%Read More | Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ moleculeRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Schmid TimothyOfficer (EVP, WW Chair, MedTech) | Option | 11,070 36,517 held | $131.94 | 09/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in JNJ
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TRI LOCUM PARTNERS LP | 13.3 % (-6.3 %) | 107.92 M | 424.94 K | 2.52% ( 10.44 K) |
JNJ Institutional Ownership Trends
JNJ Short Interest
Shares sold short, counted twice a month.
0.7%
Short % of Float
of tradable shares sold short
16.8M
Shares Sold Short
-24.0% vs prior count
2.0 Low
Days to Cover
trading days of normal volume to buy every short share back
8.5M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How JNJ ranks across every disease it competes in
Competitive Position is a premium feature
See how JNJ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialJNJ News
JNJ▲ +1.9%today
Johnson & Johnson to Host Enterprise Business Review
Johnson & Johnson will host an Enterprise Business Review on December 8, 2026, for investors. The event will cover the Innovative Medicine and MedTech sectors, featuring insights from company leaders on growth strategies and product innovations. Attendees can expect presentations, product demonstrations, and Q&A sessions.
Read more →JNJ▲ +1.9%today
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
Johnson & Johnson reported a 77% overall response rate for RYBREVANT FASPRO in first-line treatment of advanced head and neck cancer. The study showed deep and durable responses, with 65% ongoing at the clinical cutoff. These results support the ongoing Phase 3 OrigAMI-5 study and highlight the dual-targeting approach's effectiveness.
Read more →JNJ▲ +1.9%today
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
Johnson & Johnson announced promising Phase 1 results for JNJ-6143, showing a 75% tumor response rate in advanced prostate cancer patients. In the study, 77% of patients achieved a PSA reduction of at least 50%. The results suggest a potential new treatment option for patients with limited options due to disease progression.
Read more →JNJJohnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer
Johnson & Johnson announced that apalutamide plus hormone therapy significantly reduces the risk of recurrence or death by 62% compared to surgery alone in high-risk localized prostate cancer. The PROTEUS substudy showed a 51% lower risk of metastasis or death over time. These findings were presented at the ESMO Congress 2026.
Read more →JNJJohnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
Johnson & Johnson announced that its treatment ERLEADA® (apalutamide) significantly reduces the risk of recurrence or death by 62% in high-risk prostate cancer patients compared to surgery alone. The Phase 3 PROTEUS substudy also indicated a 51% lower risk of metastasis. These findings were presented at the ESMO Congress 2026.
Read more →JNJEuropean Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse
The European Commission has approved Johnson & Johnson's TECVAYLI® (teclistamab) monotherapy for adult patients with relapsed/refractory multiple myeloma. This approval is based on Phase 3 results showing a 71% reduction in disease progression risk and a 40% reduction in mortality risk compared to standard care. Teclistamab is now available as a second-line treatment option.
Read more →JNJJohnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026
Johnson & Johnson presented promising data on its VARIPULSE Pro and OMNYPULSE platforms at APHRS 2026. The VARIPULSE Pro showed 100% acute procedural success with a 0.4% adverse event rate. Meanwhile, the OMNYPULSE platform demonstrated an 82.5% success rate in preventing atrial arrhythmia recurrence at 12 months. Both platforms aim to enhance atrial fibrillation treatment.
Read more →JNJJohnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half
Johnson & Johnson has launched the Shockwave C2 Aero Fly Coronary IVL Catheter, which cuts treatment time for coronary artery disease in half. This next-generation device delivers pulses at 2 Hz, enhancing efficiency and reducing ischemic time for patients. The catheter builds on the features of its predecessor, offering improved deliverability and repositioning capabilities.
Read more →JNJJohnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn’s disease and expanding evidence in perianal fistula
Johnson & Johnson announced new data on TREMFYA® (guselkumab) showing impressive three-year outcomes for patients with moderate to severe Crohn's disease. The Phase 3 GALAXI studies revealed a clinical remission rate of 94% and endoscopic remission of 52%. Additionally, the FUZION study indicated maintained fistula remission, highlighting guselkumab's long-term efficacy and safety in managing Crohn's disease.
Read more →JNJJohnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
Johnson & Johnson has announced new data from the Phase 3 FUZION study, demonstrating that TREMFYA (guselkumab) is the only IL-23 inhibitor to achieve durable fistula remission in Crohn's disease over 48 weeks. The study showed an increase in combined fistula remission rates from 28% at Week 24 to 35% at Week 48 for the 100 mg dose group. These findings reinforce the drug's efficacy and safety profile in treating this challenging condition.
Read more →JNJCHMP recommends approval of Johnson & Johnson’s TALVEY®▼ (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma
The CHMP has recommended the approval of Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed/refractory multiple myeloma. This recommendation is based on promising Phase 3 trial results, which demonstrated significant improvements in both progression-free survival and overall survival rates. The combination therapy uniquely targets myeloma cells while minimizing impact on healthy immune cells, marking a potential advancement in treatment options.
Read more →JNJ▼ -5.7%on this newsshared move
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
Johnson & Johnson has announced a quarterly cash dividend of $1.34 per share for the fourth quarter of 2026. This dividend will be payable on December 8, 2026, to shareholders on record as of November 24, 2026. The announcement underscores the company's commitment to returning value to its shareholders.
Read more →JNJ▼ -5.7%on this newsshared move
Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
Johnson & Johnson reported a 5.9% increase in third-quarter sales for 2026, reaching $25.4 billion. The company raised its full-year guidance, anticipating reported sales of $101.2 billion and adjusted EPS of $11.10. Despite a significant drop in net earnings due to litigation charges and acquisitions, the firm highlighted strong operational performance and notable innovations in medical technology and pharmaceuticals.
Read more →JNJ▼ -5.7%on this newsshared move
TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
Johnson & Johnson announced promising results from the Phase 3 GALAXI studies, showing that TREMFYA (guselkumab) maintains clinical and endoscopic remission in adults with moderately to severely active Crohn's disease over three years. The data revealed high remission rates, with 94% of patients achieving clinical remission and 88% maintaining corticosteroid-free remission. The findings underscore the drug's potential for long-term disease management.
Read more →JNJ▼ -5.7%on this newsshared move
New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
Johnson & Johnson announced new Phase 3 data for TREMFYA (guselkumab), showing consistent perianal fistula remission in adults with Crohn's disease. The findings, presented at the ACG 2026 Annual Meeting, indicate efficacy across various patient subgroups, including those with prior biologic exposure. TREMFYA achieved remission rates of 28% compared to 10% for placebo. This trial marks a significant advancement in treating this challenging condition.
Read more →JNJNew Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
Johnson & Johnson has announced promising two-year results from its Phase 3 ICONIC-LEAD study of ICOTYDE (icotrokinra) for treating moderate-to-severe plaque psoriasis in adults and adolescents. The data, presented at the Fall Clinical Dermatology conference, showed that nearly 75% of patients achieved clear or almost clear skin, with a consistent safety profile and no new safety concerns. These results highlight ICOTYDE's potential as a transformative treatment option.
Read more →JNJJohnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
Johnson & Johnson announced positive results from the Phase 3 ICONIC-TOTAL study for ICOTYDE (icotrokinra), demonstrating its effectiveness in treating plaque psoriasis over two years. The study showed significant skin clearance in patients with high-impact psoriasis sites, with no new safety concerns. This positions ICOTYDE as a promising first-line systemic therapy.
Read more →JNJNew Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause
Johnson & Johnson's new survey reveals that while most women understand menopause affects mood and sleep, only 40% associate it with changes in eye health. The survey highlights a significant gap in awareness, with many women not seeking necessary eye care. The company, alongside Naomi Watts and the American Optometric Association, aims to encourage women to prioritize eye health during midlife.
Read more →JNJJohnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)
Johnson & Johnson has announced new data on IMAAVY (nipocalimab-aahu) for treating generalized myasthenia gravis (gMG), highlighting sustained disease control and improved patient outcomes over a two-year period. The findings indicate significant improvements in daily functioning and muscle strength, along with a reduction in corticosteroid use. Additionally, a survey revealed that many patients previously dissatisfied with their treatment experienced positive results after switching to IMAAVY.
Read more →About Johnson & Johnson
HeadquartersONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ, 08933
BIOPHARMAWATCH ELITE PLUS
Trade the next JNJ catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime